Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Bioengineered 12 , 52795288 (2021)
CPP-CAND exhibits selective senolytic activity Doxorubicin is known to induce senescence in the A375 melanoma cell line 25
Dec 2017;21(4):821-828
Description KLOW (KPV + BPC-157 + TB-500 + GHK-Cu) | Research Peptide Blend KLOW Advance your benchwork with KLOW, a multi-peptide research blend combining four well-studied molecules at lab-grade purity: KPV (10 mg), BPC-157 (10 mg), TB-500 (10 mg), and GHK-Cu (50 mg)
B.FosterJ.CarvelliL.HenryL
BPC-157 complements these mechanisms through its activation of VEGFR2 and eNOS pathways that promote angiogenesis and improve endothelial function, with the peptide's nitric oxide generation supporting vasodilation and reducing thrombotic risk while its growth factor sensitization enhances vascular responses to ischemic conditions
